Precision biosciences inc stock.

Nov 24, 2023 · Precision Biosciences Inc (NASDAQ:DTIL)’s traded shares stood at 0.64 million during the latest session, with the company’s beta value hitting 1.50. At the last check today, the stock’s price was $0.41, to imply a decrease of -3.21% or -$0.01 in intraday trading. The DTIL share’s 52-week ...

Precision biosciences inc stock. Things To Know About Precision biosciences inc stock.

Nov 29, 2023 · View Precision BioSciences, Inc DTIL investment & stock information. Get the latest Precision BioSciences, Inc DTIL detailed stock quotes, stock data, Real-Time ECN, charts, stats and more. Business Wire. DURHAM, N.C., March 27, 2023 -- ( BUSINESS WIRE )--Precision BioSciences, Inc. (Nasdaq: DTIL) a clinical stage gene editing company developing ARCUS®-based ex vivo allogeneic CAR T ...Find the latest Precision BioSciences, Inc. (PBS.F) stock quote, history, news and other vital information to help you with your stock trading and investing.Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing …Mar 9, 2023 · DURHAM, N.C., March 09, 2023--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS®-based ex vivo allogeneic CAR T and in vivo gene editing therapies ...

Business Wire. DURHAM, N.C., March 27, 2023 -- ( BUSINESS WIRE )--Precision BioSciences, Inc. (Nasdaq: DTIL) a clinical stage gene editing company developing ARCUS®-based ex vivo allogeneic CAR T ...Given the current short-term trend, the stock is expected to fall -4.66% during the next 3 months and, with a 90% probability hold a price between $0.264 and ...Precision BioSciences, Inc. announced that it has received final meeting minutes from its recent Type B End of Phase 1 meeting with the U.S. Food and Drug Administration for its lead investigational...

Common stock . This is an initial public offering of shares of common stock by Precision BioSciences, Inc. We are offering shares of our common stock. The initial public offering price is expected to be between $ and $ per share. Prior to this offering, there has been no public market for our common stock.

The Precision BioSciences Inc. stock price fell by -9.31% on the last day (Wednesday, 29th Nov 2023) from $0.408 to $0.370. During the last trading day the stock fluctuated 15.44% from a day low at $0.360 to a day high of $0.416. The price has risen in 6 of the last 10 days and is up by 6.78% over the past 2 weeks.Precision BioSciences, Inc. announced that it has received final meeting minutes from its recent Type B End of Phase 1 meeting with the U.S. Food and Drug Administration for its lead investigational...Precision BioSciences, Inc. is a clinical stage biotechnology company dedicated to improving life (DTIL) with its novel and proprietary ARCUS genome editing platform. ARCUS is a highly precise and versatile genome editing platform that was designed with therapeutic safety, delivery, and control in mind.Discover historical prices for DTIL stock on Yahoo Finance. View daily, weekly or monthly format back to when Precision BioSciences, Inc. stock was issued.

Given the current short-term trend, the stock is expected to fall -4.66% during the next 3 months and, with a 90% probability hold a price between $0.264 and ...

View 13F filing holders of Precision BioSciences Inc. 13F filings are submitted quarterly to the SEC by hedge funds and other investment managers.

Weighted average shares of common stock outstanding were approximately 110.8 million for the quarter ended September 30, 2022, as compared to approximately 59.7 million for the quarter ended September 30, 2021. ... Precision BioSciences, Inc. Condensed Consolidated Statements of Operations (In thousands, except share and per …What are individual investors saying about Precision BioSciences? View the latest DTIL social media trends at MarketBeat. Skip to main content. S&P 500 4,594.63 (+0.59%) DOW 36,245.50 (+0.82%) ... Stock Ideas and Recommendations. Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the …WebJun 22, 2023 · Stifel Nicolaus Adjusts Precision BioSciences Price Target to $9 From $11, Maintains Buy Rating. Goldman Sachs Adjusts Precision BioSciences' Price Target to $2 From $3, Keeps Neutral Rating. More news. Press releases Precision BioSciences, Inc. Precision BioSciences Reports Second Quarter 2023 Financial Results and Provides Business Update. Strong balance sheet of ~$373.1 million cash, cash equivalents and marketable securities as of December 31, 2022 is anticipated to fund planned op... SOUTH SAN FRANCISCO, Calif., March 7, 2023 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasda...Precision BioSciences, Inc. is a clinical stage biotechnology company dedicated to improving life (DTIL) with its novel and proprietary ARCUS genome editing platform. ARCUS is a highly precise and versatile genome editing platform that was designed with therapeutic safety, delivery, and control in mind.Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS®-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced an upcoming scientific presentation of preclinical data from its PBGENE-HBV program.PBGENE-HBV is designed to potentially eliminate hepatitis B …INE191C01015. Precision Containeurs Ltd. engages in the manufacture of barrels and trades CRCA coils. It manufactures small, intermediate, and large plastic and metal …

Get Precision BioSciences Inc (DTIL.O) real-time stock quotes, news, price and financial information from Reuters to inform your trading and investmentsCorporate Profile Precision BioSciences, Inc. (Nasdaq: DTIL), is a clinical stage biotechnology company dedicated to improving life (DTIL) with its novel and proprietary …DURHAM, N.C.--(BUSINESS WIRE)--Nov. 7, 2023-- Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary …Precision BioSciences' stock was trading at $1.19 at the start of the year. Since then, DTIL stock has decreased by 69.3% and is now trading at $0.3650. View the …Is "Precision Biosciences Inc" a Good Investment? Current price today: △0.424 USD (+1.631%). 7 Days Forecast. Get It Now!Mar 9, 2023 · DURHAM, N.C., March 09, 2023--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS®-based ex vivo allogeneic CAR T and in vivo gene editing therapies ... November 7, 2023 at 4:54 AM · 3 min read. Revenues for Q3 2023 were $13.1 million, a significant increase from $7.4 million in Q3 2022. Net loss for the quarter was $8.1 million, or $ (0.07) per ...

Jun 21, 2022 · DURHAM, N.C.--(BUSINESS WIRE)--Jun. 21, 2022-- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced that it has agreed to sell 35,971,224 shares of its common stock at a price of $1.39 per share, by way of an underwritten offering, for gross proceeds of approximately ...

Complete Precision Biosciences Inc. stock information by Barron's. View real-time DTIL stock price and news, along with industry-best analysis. The stock of Precision Biosciences Inc (NASDAQ: DTIL) has decreased by -9.31 when compared to last closing price of 0.41.Despite this, the company has seen a loss of -11.84% in its stock price over the last five trading days. Business Wire reported 2023-10-23 that DURHAM, N.C.–(BUSINESS WIRE)–Precision BioSciences, Inc. …Precision BioSciences, Inc. (DTIL) Stock Price, Quote, News & Analysis DTIL Precision BioSciences, Inc. Stock Price & Overview $0.37 0.0099 ( +2.79%) 3:59 …DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS®-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced that it will publish financial results for the first quarter 2023 and provide a business update on May 9, 2023.About …Precision BioSciences has sold its lead cell therapy asset as the company shifts focus exclusively to gene editing. ... Precision's stock, for instance, closed Monday at $0.45 a share, ...Get the latest Pressure Biosciences Inc (PBIO) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions.WebFounders Derek Jantz, Jeff Smith, Matthew Kane. Operating Status Active. Last Funding Type Post-IPO Equity. Legal Name Precision BioSciences, Inc. Stock Symbol NASDAQ:DTIL. Company Type For Profit. Contact Email [email protected]. Phone Number +1 919 314-5512. Precision …Web

Precision Biosciences, Inc. Condensed Balance Sheets Data (In thousands, except share amounts) (Unaudited) June 30, 2023: December 31, 2022: Cash and cash equivalents $ 137,794 $ 189,576 Working capital 91,465 139,441 Total assets 181,697 238,169 Total liabilities 147,656 177,736 Total stockholders' equity $ 34,041 $ 60,433 Common stock outstanding

Nov 7, 2023 · DURHAM, N.C., November 07, 2023 -- ( BUSINESS WIRE )--Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in ...

Information on stock, financials, earnings, subsidiaries, investors, and executives for Precision BioSciences ... Precision BioSciences Inc is a genome editing ...Precision BioSciences, Inc. 302 East Pettigrew Street Suite A-100 Durham, NC 27701 United States 919 314 5512 https://www.precisionbiosciences.com Sector(s) : Healthcare Industry : Biotechnology ...H.C. Wainwright analyst Patrick Trucchio maintained a Buy rating on Precision BioSciences ( DTIL – Research Report) today and set a price target of $17.00. The company’s shares opened today at ...The increase in weighted average shares of common stock outstanding was primarily due to a $50 million underwritten offering of common stock and Novartis’ $25 million equity investment in 2022. About Precision BioSciences, Inc.Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene insertion, excision, and elimination, today announced that the company will present at Hep-DART 2023 in an …Web4 thg 4, 2019 ... This short video shares the story of the origins of Precision BioSciences through interviews with its founding members.Individuals with disabilities: if you are a qualified individual with a disability and are unable or limited in your ability to use or access the online application system process due to your disability, please contact our disability applications assistant at 919-314-5512 to request assistance. Precision BioSciences provides reasonable ...November 28, 2023. DURHAM, N.C. -- (BUSINESS WIRE)--Nov. 28, 2023-- Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene insertion, excision, and elimination,...

According to the issued ratings of 3 analysts in the last year, the consensus rating for Precision BioSciences stock is Moderate Buy based on the current 1 hold rating and 2 buy ratings for DTIL. The average twelve-month price prediction for Precision BioSciences is $3.00 with a high price target of $4.00 and a low price target of $2.00.cb67aba6c16954c05dcceb4.1l1zKTVo6ersm5eXVf8wh_Dbso85lTxzWqCKCr_Iz1A.rjM0dlMnjI6PrcXmELNHw8H28PZ7_1NEPpTERcqhoRGdFwFCQh_Z2qPN3gWebPrecision BioSciences, Inc. is an advanced gene editing company dedicated to improving life (DTIL) with its novel and proprietary ARCUS® genome editing platform that differs from other technologies in the way it cuts, its smaller size, and its simpler structure. Key capabilities and differentiating characteristics may enable ARCUS …WebInstagram:https://instagram. how to start trading forex for beginnerspenny stocks on webullcalifornia resources corpunited states gold bar price Apr 28, 2023 · On April 24, 2023, Precision BioSciences, Inc. (the "Company") received a letter (the "Nasdaq Staff Deficiency Letter") from the Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq") indicating that, for the last 30 consecutive business days, the closing bid price for the Company's common stock has been below the minimum ... Precision BioSciences, Inc is a clinical-stage gene editing company. It is developing ex vivo allogeneic chimeric antigen receptor (CAR) T immunotherapies and in vivo therapies for genetic and infectious diseases with the application of its owned ARCUS genome editing platform. best real estate to invest in 2023bmea Feb 24, 2023 · About Precision BioSciences, Inc. Precision BioSciences, Inc. is a clinical stage biotechnology company dedicated to improving life (DTIL) with its novel and proprietary ARCUS® genome editing platform. ARCUS is a highly precise and versatile genome editing platform that was designed with therapeutic safety, delivery, and control in mind. Cogent Biosciences, Inc. is a biotechnology company that is focused on developing precision therapies for genetically defined diseases. The Company's advanced clinical program, bezuclastinib (CGT9486), is a selective tyrosine kinase inhibitor that is designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT … engagement ring insurance comparison DURHAM, N.C.--(BUSINESS WIRE)--Jun. 21, 2022-- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced that it has agreed to sell 35,971,224 shares of its common stock at a price of $1.39 per share, by way of an underwritten offering, for gross proceeds of approximately ...DTIL Precision Biosciences Inc Stock - Share Price, Short Interest, Short Squeeze, Borrow Rates (NASDAQ)